What is the value of oncology medicines?

Coverage with evidence development (CED), rather than quality-adjusted-life-year (QALY) thresholds, offers the best way forward in balancing evidence-based policy for new oncology products

with the needs of developers, payers, physicians and patients. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution

RELEVANT ARTICLES Open Access articles citing this article. * RISK-SHARING AGREEMENTS IN THE EU: A SYSTEMATIC REVIEW OF MAJOR TRENDS * Trevor Jozef Piatkiewicz * , Janine Marie Traulsen *  

& Tove Holm-Larsen _PharmacoEconomics - Open_ Open Access 18 July 2017 * BALANCING COSTS AND BENEFITS AT DIFFERENT STAGES OF MEDICAL INNOVATION: A SYSTEMATIC REVIEW OF MULTI-CRITERIA

DECISION ANALYSIS (MCDA) * Philip Wahlster * , Mireille Goetghebeur *  … Peter Kolominsky-Rabas _BMC Health Services Research_ Open Access 09 July 2015 ACCESS OPTIONS Access through your

institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access

to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read

our FAQs * Contact customer support REFERENCES * Yabroff, K. & Schrag, D. _J. Natl. Cancer Inst._ 101, 1161–1163 (2009). Article  Google Scholar  * Institute of Medicine. _Crossing the

Quality Chasm: A New Health System for the Twenty-First Century_ (National Academy of Sciences, Washington, DC, 2001). * Mulcahy, N. Time to consider cost in evaluating cancer drugs in the

United States? <http://www.medscape.com/viewarticle/705689> (2009). * Fojo, T. & Grady, C. _J. Natl. Cancer Inst._ 101, 1044–1048 (2009). Article  Google Scholar  *

Anonymous. CDC Faststats (Centers for Disease Control and Prevention, Washington, DC, USA) <http://www.cdc.gov/nchs/FASTATS/cancer.htm> (Accessed, November 1, 2009). *

Eckhouse, S., Lewison, G. & Sullivan, R. _Mol. Oncol._ 2, 20–32 (2008). Article  Google Scholar  * Eckhouse, S. & Sullivan, R. _PLoS Med._ 3, e267 (2006). Article  Google Scholar  *

DiMasi, J. & Grabowski, H. _J. Clin. Oncol._ 25, 209–216 (2007). Article  Google Scholar  * Reichert, J. & Wenger, J. _Drug Discov. Today_ 13, 30–37 (2008). Article  CAS  Google

Scholar  * Teutsch, S., Berger, M. & Weinstein, M. _Health Aff._ 24, 128–132 (2005). Article  Google Scholar  * Gafni, A. & Birch, S. _Soc. Sci. Med._ 62, 2091–2100 (2006). Article 

Google Scholar  * Raftery, J. _J. Eval. Clin. Pract._ 5, 361–366 (2001). Article  Google Scholar  * Nord, E. _Med. Decis. Making_ 15, 201–208 (1995). Article  CAS  Google Scholar  * Cohen,

J. _J. Med. Ethics_ 22, 267–272 (1996). Article  CAS  Google Scholar  * Tsuchiya, A. _Health Econ._ 9, 57–68 (2000). Article  CAS  Google Scholar  * Clement, F., Harris, A. & Jing Li, J.

_J. Am. Med. Assoc._ 302, 1437–1443 (2009). Article  CAS  Google Scholar  * Mason, A. & Drummond, M. _Eur. J. Cancer_ 45, 1188–1192 (2009). Article  Google Scholar  * Tangka, F.K. et

al. _Cancer_ 116, 3477–3484 (2010). Article  Google Scholar  * Jonsson, B. & Wilking, N. _Ann. Oncol._ 18 Suppl 3, iii2–iii7 (2007). Google Scholar  * Verdecchia, A. et al. _Eur. J.

Public Health_ 18, 527–532 (2008). Article  Google Scholar  * Gatta, G. et al. _Cancer_ 89, 893–900 (2000). Article  CAS  Google Scholar  * Verdecchia, A. et al. _Lancet Oncol._ 8, 784–796

(2007). Article  Google Scholar  * Schiller, J. _Clin. Cancer Res._ 11, 5030s–5032s (2005). Article  Google Scholar  *

<http://info.cancerresearchuk.org/news/archive/cancernews/2009-11-03-Lung-cancer-experts-call-for-improvements-in-NHS-care> * Cohen, J., Cairnes, C., Paquette, C. & Faden,

L. _J. App. Health Econ. Health Pol._ 5, 177–187 (2006). Article  Google Scholar  * Cohen, J. & Wilson, A. _mAbs_ 1, 56–66 (2009). Article  Google Scholar  * Anonymous. NICE Guidance

(National Health Service, London) <http://guidance.nice.org.uk/TA169> (Accessed November 1, 2009). * Anonymous. Pfizer's sutent is recommended as first-line treatment for

kidney cancer patients by British health agency. <http://www.medicalnewstoday.com/articles/138010.php> (2009). * Leveque, D. _Lancet Oncol._ 9, 1102–1107 (2008). Article 

Google Scholar  * Cohen, J., Wilson, A. & Faden, L. _Food Drug Law J._ 64, 391–403 (2009). PubMed  Google Scholar  * Singer, P. Why we must ration health care. _New York Times Magazine_

(July 19, 2009). * Leighl, N., Tsao, W., Zawisza, D., Nematollahi, M. & Shepherd, F. _Lung Cancer_ 51, 115–121 (2006). Article  Google Scholar  * Markman, M. _J. Oncol. Pract._ 4, 262

(2008). Article  Google Scholar  * Mohr, P. & Tunis, S. _Pharmacoeconomics_ 28, 153–162 (2010). Article  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS *

Joshua Cohen is at Tufts University School of Medicine, Center for the Study of Drug Development, Boston, Massachusetts, USA, Joshua Cohen * William Looney is at Pfizer, New York, New York,

USA., William Looney Authors * Joshua Cohen View author publications You can also search for this author inPubMed Google Scholar * William Looney View author publications You can also

search for this author inPubMed Google Scholar ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing financial interests. RIGHTS AND PERMISSIONS Reprints and permissions

ABOUT THIS ARTICLE CITE THIS ARTICLE Cohen, J., Looney, W. What is the value of oncology medicines?. _Nat Biotechnol_ 28, 1160–1163 (2010). https://doi.org/10.1038/nbt1110-1160 Download

citation * Published: 05 November 2010 * Issue Date: November 2010 * DOI: https://doi.org/10.1038/nbt1110-1160 SHARE THIS ARTICLE Anyone you share the following link with will be able to

read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing

initiative